These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33289663)

  • 21. Tigecycline: an update.
    Stein GE; Babinchak T
    Diagn Microbiol Infect Dis; 2013 Apr; 75(4):331-6. PubMed ID: 23357291
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic and pharmacodynamic evaluation of tigecycline.
    Giamarellou H; Poulakou G
    Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1459-70. PubMed ID: 21958044
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies.
    Bassetti M; Eckmann C; Bodmann KF; Dupont H; Heizmann WR; Montravers P; Guirao X; Capparella MR; Simoneau D; Sánchez García M
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii5-14. PubMed ID: 23772047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequency of the off-label use of antibiotics in clinical practice: a systematic review.
    Tansarli GS; Rafailidis PI; Kapaskelis A; Falagas ME
    Expert Rev Anti Infect Ther; 2012 Dec; 10(12):1383-92. PubMed ID: 23253317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Failure of tigecycline to treat severe Clostridium difficile infection.
    Kopterides P; Papageorgiou C; Antoniadou A; Papadomichelakis E; Tsangaris I; Dimopoulou I; Armaganidis A
    Anaesth Intensive Care; 2010 Jul; 38(4):755-8. PubMed ID: 20715744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Off-label drug prescriptions among outpatient children and adolescents in Germany--a database analysis].
    Sonntag D; Trebst D; Kiess W; Kapellen T; Bertsche T; Kostev K
    Dtsch Med Wochenschr; 2013 Oct; 138(44):2239-45. PubMed ID: 24150699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution.
    Chemaly RF; Hanmod SS; Jiang Y; Rathod DB; Mulanovich V; Adachi JA; Rolston KV; Raad II; Hachem RY
    Medicine (Baltimore); 2009 Jul; 88(4):211-220. PubMed ID: 19593226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Off-label use of antibiotics in hospitalized patients: focus on tigecycline.
    Curcio D
    J Antimicrob Chemother; 2009 Dec; 64(6):1344-6. PubMed ID: 19759045
    [No Abstract]   [Full Text] [Related]  

  • 29. Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
    Liang CA; Lin YC; Lu PL; Chen HC; Chang HL; Sheu CC
    Clin Microbiol Infect; 2018 Aug; 24(8):908.e1-908.e7. PubMed ID: 29108947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of tigecycline monotherapy versus combination therapy for the treatment of hospital-acquired pneumonia (HAP): a meta-analysis of cohort studies.
    Bai XR; Liu JM; Jiang DC; Yan SY
    J Chemother; 2018 May; 30(3):172-178. PubMed ID: 29405898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
    Garrison MW; Neumiller JJ; Setter SM
    Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes in patients infected with carbapenem-resistant Acinetobacter baumannii and treated with tigecycline alone or in combination therapy.
    Guner R; Hasanoglu I; Keske S; Kalem AK; Tasyaran MA
    Infection; 2011 Dec; 39(6):515-8. PubMed ID: 21789524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Off-label prescriptions in Italian hospices: a national survey.
    Toscani F; Di Giulio P; Campi R; Pellerin I; De Luca A; Casale G;
    J Pain Symptom Manage; 2009 Sep; 38(3):365-71. PubMed ID: 19564095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Clinical Overview of Off-label Use of Gabapentinoid Drugs.
    Goodman CW; Brett AS
    JAMA Intern Med; 2019 May; 179(5):695-701. PubMed ID: 30907944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.
    Maher AR; Theodore G
    J Manag Care Pharm; 2012 Jun; 18(5 Suppl B):S1-20. PubMed ID: 22784311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical efficacy of tigecycline used as monotherapy or in combination regimens for complicated infections with documented involvement of multiresistant bacteria.
    Heizmann WR; Löschmann PA; Eckmann C; von Eiff C; Bodmann KF; Petrik C
    Infection; 2015 Feb; 43(1):37-43. PubMed ID: 25367409
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients.
    Postier RG; Green SL; Klein SR; Ellis-Grosse EJ; Loh E;
    Clin Ther; 2004 May; 26(5):704-14. PubMed ID: 15220014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical experience with tigecycline in the treatment of carbapenem-resistant Acinetobacter infections.
    Metan G; Alp E; Yildiz O; Percin D; Aygen B; Sumerkan B
    J Chemother; 2010 Apr; 22(2):110-4. PubMed ID: 20435570
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the ratio of the estimated area under the concentration-time curve to minimum inhibitory concentration (estimated AUIC) as a predictor of the outcome for tigecycline treatment for pneumonia due to multidrug-resistant bacteria in an intensive care unit.
    Xu Y; Jin L; Liu N; Luo X; Dong D; Tang J; Wang Y; You Y; Liu Y; Chen M; Yu Z; Hao Y; Gu Q
    Int J Infect Dis; 2019 May; 82():79-85. PubMed ID: 30878630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.